FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)

Genentech, Inc. announced today that the U.S. FDA Oncologic Drugs Advisory Committee (ODAC) voted unanimously that the response seen with Avastin (bevacizumab) in people with previously treated glioblastoma is of sufficient magnitude to be reasonably likely to predict clinical benefit.

The details can be read here.